The Role of Cytochrome P450 in Cytotoxic Bioactivation: Future Therapeutic Directions

Current Cancer Drug Targets

Volumn 4, Issue 3, 2004, Pages 257-265

  Rooney, P H ^a,b   Telfer, C ^b   McFadyen, M C E ^a   Melvin, W T ^b   Murray, G I ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b Auvation Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS[[2 (DIMETHYLAMINO N OXIDE)ETHYL]AMINO] 5,8 DIHYDROXYANTHRAQUINONE; 2 (4 AMINO 3 METHYLPHENYL)BENZOTHIAZOLE; 5 FLUORO 2 (4 LYSYLAMINO 3 METHYLPHENYL)BENZOTHIAZOLE; AMINOPHENOL DERIVATIVE; ANTINEOPLASTIC AGENT; BENZOTHIAZOLE DERIVATIVE; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOTOXIC AGENT; IFOSFAMIDE; ISOENZYME; NSC 703786; PRODRUG; TAMOXIFEN; TEGAFUR; THIOTEPA; UNCLASSIFIED DRUG;

ARACHIDONIC ACID METABOLISM; CANCER; CANCER CELL; CATALYSIS; CHOLESTEROL METABOLISM; CLINICAL TRIAL; DRUG ACTIVATION; DRUG DESIGN; DRUG DETOXIFICATION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME ACTIVITY; GASTROINTESTINAL TRACT; GENE THERAPY; HUMAN; LIPID METABOLISM; LIVER; NONHUMAN; PROTEIN EXPRESSION; REVIEW; STEROID METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; GENE THERAPY; HUMANS; VARIATION (GENETICS);

EID: 2342429738     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009043333014     Document Type: Review

References (83)

1. Rendic, S. Summary of Information on the Human CYP Enzymes. Drug Metab. Rev. 2002, 34, 83-448.
2. Nebert, D. W.; Russell D. W. Clinical importance of the Cytochromes P450. Lancet 2002, 360, 1155-1162.
3. Nelson, D. R. Introductory Remarks on Human CYPs. Drug Metab. Rev. Drug Discov. 2002, 34, 1-15. http://drnelson.utmem.edu/human.P450.table.html (accessed Nov 12, 2003).
4. Willson, T. M.; Kliewer, S. A. PXR, CAR and Drug Metabolism. Nature Rev. Drug Discov. 2002, 1, 259-266.
5. Xie, W.; Barwick, J. L.; Downes, M.; Blumberg, B.; Simon, C. M.; Nelson, M. C.; Neuschwander-Tetri, B. A.; Bruntk, E. M.; Guzelian, P. S.; Evans, R. M. Humanized Xenobiotic Response in Mice Expressing Nuclear Receptor SXR. Nature 2000, 406, 453-439.
6. Staudlinger, J. L.; Liu, Y. P.; Madan, A.; Habeebu, S.; Klaassen, C. D. Coordinate Regulation of Xenobiotic and Bile Acid Homeostasis By Pregnane X Receptor. Drug Metab. Dispos. 2001, 29, 1467-1472.
7. Qiang, M. Induction of CYP1A1, the AhR/DRE Paradigm; Transcription, Receptor Regulaton, and Expanding Biological Roles. Curr. Drug Metab. 2001, 2, 149-164.
8. McFadyen, M. C. E.; Rooney, P. H.; Melvin, W. T.; Murray, G. I. Quantitative Analysis of the Ah Receptor/Cytochrome P450. CYP1B1/CYP1A1 Signalling Pathway. Biochem. Pharmacol. 2003, 65, 1663-1674.
9. Edwards, R. J.; Adams, D. A.; Watts, P. S.; Davies, D. S.; Boobis, A. R. Development of A Comprehensive Panel of Antibodies Against the Major Xenobiotic Metabolising Forms of Cytochrome P450 in Humans. Biochem. Pharmacol. 1998, 34, 83-448.
10. Sai, Y.; Dai, R.; Yang, T. J.; Krausz, K. W.; Gonzalez, F. J.; Gelbion, H. V.; Shou, M. Assessment of Specificity of Eight Chemical Inhibitors Using cDNA-Expressed Cytochrome P450. Xenobiotica. 2000, 4, 327-343.
11. Shou, M.; Lu, T.; Krausz, K. W.; Sai, Y.; Yang, T.; Korzekwa, K. R.; Gonzalez, F. J.; Gelboin, H. V. Use of Inhibitory Monoclonal Antibodies To Assess the Contribution of Cytochromes P450 To Human Drug Metabolism. Eur. J Pharmacol. 2000, 394, 199-209.
12. Marez, D.; Legrand, M.; Sabbagh, N.; Guidice, J. M.; Spire, C.; Lafitte, J. J.; Meyer, U. A.; Broly, F. Polymorphism of the Cytochrome P450 CYP2D6 Gene in A European Population: Characterization of 48 mutations and 53 Alleles, Their Frequencies and Evolution. Pharmacogenetics 1997, 7, 193-202.
13. Yu, A.; Kneller B. M.; Rettie, A. E.; Haining, R. L. Expression, Purification, Biochemical Characterization, and Comparative Function of Human Cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 Allelic Isoforms. J. Pharmacol. Exp Ther. 2002, 303, 1291-1300.
14. Lamba, J. K.; Lin, Y. S.; Thummel, K.; Daly, A.; Watkins, P. B.; Strom, S.; Zhang, J.; Schuetz, E. G. Common Allelic Variants of Cytochrome P4503A4 and Their Prevalence in Different Populations. Pharmacogenetics 2002, 12, 121-132.
15. Xu, C.; Goodz, S.; Sellers, E. M.; Tyndale, R. F. CYP2A6 Genetic Variation and Potential Consequences. Adv. Drug. Del. Rev. 2002, 54, 1245-1256.
16. Zhang, X.; Su, T.; Zhang, Q-Y.; Gu, J.; Gaggana, M.; Li, H.; Ding, Z. Genetic Polymorphisms of Human CYP2A13 Gene: Identification of Single-Nucleotide Polymorphisms and Functional Characterization of An Arg257Cys Variant. J. Pharmacol. Exp. Ther. 2002, 302, 416-423.
17. Xie, H. G.; Parsad, H. C.; Kim, R. B.; Stein, M. CYP2C9 Allelic Variants: Ethnic Distribution and Functional Significance. Adv. Drug. Del. Rev. 2002, 54, 1257-1270.
18. Van der Weide, J.; Steijns, L. S. W. Cytochrome P450 Enzyme Systems: Genetic Polymorphisms and Impact on Clinical Pharmacology. Annu. Clin. Biochem. 1999, 36, 722-729.
19. Kuehl, P.; Zhang, J.; Lin, Y.; Lamba, J.; Assem, M.; Schuetz, J.; Watkins, P. B.; Daly, A.; Wrighton, S. A.; Hall, S. D.; Maurel, P.; Relling, M. ; Brimer, C.; Yasuda, K.; Venkataramanan, R.; Strom, S.; Thummel, K., Boguski, M. S.. Schuetz, E. Sequence Diversity in CYP3A Promoters and Characterisation of the Genetic Basis of Polymorphic CY3A5 Expression. Nat. Genet. 2001, 27, 383-391.
20. Tayeb, M. M.; Clark, C.; Haites, N. E.; Rooney, P. H.; Murray, G. I.; Payne, S. N. L.; McLeod, H. L. CYP3A4 Promoter Variant Is Associated With Prostate Cancer Risk in Men With Benign Prostatic Hypertrophy. Oncol. Rep. 2002, 9, 653-655.
21. Rebbeck, T. R. More About: Modification of Clinical Presentation of Prostate Tumors By A Novel Genetic Variant in CYP3A4. J. Natl. Cancer. Inst. 2000, 92, 76.
22. Amirimani, B.; Walker, A. H.; Weber, B. L.; Rebbeck, T. R. RESPONSE: Re: Modification of the Clinical Presentation of Prostate Tumors By A Novel Genetic Variant in CYP3A4. J. Natl. Cancer. Inst. 1999, 91, 1588-1590.
23. Murray, G. I. The Role of Cytochrome P450 in Tumour Development and Progression and Its Potential in Therapy. J. Pathol. 2000, 192, 419-426.
24. Patterson, L. H.; Murray, G. I. Tumour Cytochrome P450 and Drug Activation. Curr. Pharma. Des. 2002, 8, 1335-1347.
25. Sonnichsen, D. S.; Liu, Q.; Schuetz, E. G.; Schuetz, J. D.; Pappo, A.; Relling, M. V. Variability in Human Cytochrome P450 Paclitaxel Metabolism. J. Pharmacol. Exp. Ther. 1995, 23, 506-512.
26. Marre, F.; Sanderink, G. J.; deSousa, G.; Gaillard, C.; Martinet, M.; Rulmani, R. Hepatic Biotransformation of Docetaxel (Taxotere(R)) in Vitro: Involvement of the CYP3A Subfamily in Humans. Cancer Res. 1996, 56, 1296-1302.
27. Mathijssen, R. H.; van Alphen, R. J.; Verwrij, J.; Loos, W. J.; Nooter, K.; Stoter, G.; Sparreboom, A. Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11). Clin. Cancer Res. 2001, 7, 2182-2194.
28. Walle, T.; Walle, U. K.; Kumar, G. N.; Bhalla, K. N. Taxol Metabolism and Disposition in Cancer-Patients. Drug. Metab. Dispos. 1995, 23, 506-512.
29. Bardelmeijer, H.; Ouwehand, M.; Buckle, T.; Huisman, M. T.; Schellens, J. H. M.; Beijnen, J. H.; van Telligen, O. Low Systemic Exposure of Oral Docetaxel in Mice Resulting From Extensive First-Pass Metabolism Is Boosted By Ritonavir. Proc. Am. Assoc. Cancer Res. 2002, 43, 262.
30. Huizing, M. T.; Misser, V. H.; Pieters, R. C.; Huinink, W. W. T.; Veenhof, C. H. N.; Vermorken, J. B.; Pinedo, H. M.; Beijnen, J. H. Taxanes: A New Class of Antitumor Agents. Cancer Invest. 1995, 13, 381-404.
31. Chester, J. D.; Joel, S. P.; Cheeseman, S. L.; Hall, G. D.; Braun, M. S. ; Perry, J.; Davis, T.; Button, C. J.; Seymour, M. T. Phase 1 and Pharmacokinetic Study of Intravenous Irinotecan Plus Oral Ciclosporin in Patients with Fluorouracil-refractory Metastatic Colon Cancer. J. Clin. Oncol. 2003, 21, 1125-1132.
32. Kehrer, D. F. S.; Mathijssen, R. H.; Verweji, J.; de Bruijn, P.; Sparreboom, A. Modulation of Irinotecan Metabolism By Ketoconazole. J. Clin. Oncol. 2002, 14, 3122-3129.
33. Crewe, K.H.; Notley, L.M.; Wunsch, R.M.; Lennard, M.S.; Gillian, E.M.J. Metabolism of Tamoxifen By Recombinant Human Cytochrome P450 Enzymes: Formation of the 4-Hydroxyl, 4′-Hydroxyl and N-Desmethyl Metabolites and Isomerization of Trans-4-Hydroxytamoxifen. Drug Metab. Dispos. 2002, 30, 869-874.
34. Notley, L. M.; de Wolf, C. J. F.; Wunsch, R. M.; Lancaster, R. G.; Gillian, E. M. J. Bioactivation of Tamoxifen By Recombinant Human Cytochrome P450 Enzymes. Chem. Res. Toxicol. 2002, 15, 614-622.
35. Hellmold, H.; Rylander, T.; Magnusson, M.: Reihner, E.; Warner, M.; Gustafasson, J. Characterization of Cytochrome P450 Enzymes in Human Breast Tissue From Reduction Mammoplasties. J. Clin. Endrocrinol. Metab. 1998, 83, 886-895.
36. Sridar, C.; Kent, U. M.; Notley, L. M.; Gillian, E. M. J.; Hollenberg, P. F. Effect of Tamoxifen on the Enzymatic Activity of Human Cytochrome CYP2B6. J. Pharmacol. Exp. Ther. 2002, 301, 945-952.
37. Jounaidi, Y.; Hecht, J. E. D.; Waxman, D. J. Retroviral Transfer of Human Cytochrome P450 Genes For Oxazaphophorine-Based Cancer Gene Therapy. Cancer Res. 1998, 58, 4391-4401.
38. Jacobson, P. A.; Green, K.; Birnbaum, A.; Remmel, R. P. Cytochrome P450 Isozymes 3A4 and 2B6 Are Involved in the in Vitro Human Metabolism of Thiotepa To TEPA. Cancer Chemother. Pharmacol. 2002, 49, 461-467.
39. Heggie, G. D.; Sommadossi, J. P.; Cross, D. S.; Huster, W. J.; Diasio, R. B. Clinical Pharmacokinetics of 5-Fluorouracil and Its Metabolites in Plasma, Urine and Bile. Cancer Res. 1987, 47, 2203-2206.
40. Fraile, R. J.; Baker, L. H.; Buroker, T. R.; Horwitz, J.; Vaitkevicius, V. K. Pharmacokinetics of 5-Fluorouracil Administered Orally, By Rapid Intravenous and By Slow Infusion. Cancer Res. 1980, 40, 2223-2228.
41. Daigo, S.; Takahashi, Y.; Fujieda, M.; Ariyoshi, N.; Yamazaki, H.; Koizumi, W.; Tanabe, S.; Saigenji, K.; Nagayama, S.; Ikeda, K.; Nishioka, Y.; Kamataki, T. A Novel Mutant Allele of CYP2A6 gene (CYP2A*11) Found in A Cancer Patient Who Showed Poor Metabolic Phenotype Towards Tegafur. Pharmacogenetics 2002, 12, 299-306.
42. Shi, D. F.; Bradshaw, T. D.; Wrigley, S.; McCall, C. J.; Lelieveld, P.; Fichtner, I.; Stevens, M. F. G. Antitumor Benzothiazoles.3: Synthesis of 2-(4-Aminophenyl)Benzothiazoles and Evaluation of Their Activities Against Breast Cancer Cell Lines in Vitro and in Vivo. J. Med. Chem. 1996, 39, 3375-3384.
43. Bradshaw, T. D.; Wrigley, S.; Shi, D. F.; Schultz, R. J.; Paull, K. D.; Stevens, M. F. G. 2-(4-aminophenyl)benzothiazoles: Novel Agents With Selective Profiles If the in Vitro Anti-Tumour Activity. Br. J. Cancer 1998, 77, 745-752.
44. Chua, M. S.; Kashiyama, E.; Bradshaw, T. D.; Stinson, S. F.; Brantley, E.; Sausville, E. A.; Stevens, M. F. G. Role of CYP1A1 in Modulation of Antitumor Properties of the Novel Agent 2-(4-Aminophenyl) Benzothiazole (DF 203, NSC 674495) in Human Breast Cancer Cells. Cancer Res. 2000, 60, 5196-5203.
45. O'Brien, S. E.; Browne, H.L.; Bradshaw, T.D.; Westwell, A.D.; Stevens, M.F.G.; Laughton, C.A. Antitumor benzothiazoles. Part23 - Frontier Molecular Orbital Analysis Predicts Bioactivation of 2-(4-Aminophenyl)Benzothiazoles To Reactive Intermediates By Cytochrome P4501A1. Org. Biomol. Chem. 2003, 1, 493-497.
46. Hutchinson, I.; Chua, M. S.; Browne, H. L.; Trapani, V.; Bradshaw, T. D. ; Westwell, A. D.; Stevens, M. F. G. Antitumor Benzothiazoles 14, Synthesis and in Vitro Biological Properties of Fluorinated 2-(4-Aminophenyl)Benzothiazoles. J. Med. Chem. 2001, 44, 1446-1455.
47. Bradshaw, T. D.; Chua, M-S.; Browne, H. L.; Trapani, V.; Sausville, E. A.; Stevens, M. F. G. in Vitro Evaluation of Amino Acid Pro-Drugs of Novel Antitumor 2-(4-Amino-3-Methylphenyl) Benzothiazoles. Br. J. Cancer 2002, 86, 1348-1354.
48. Leong, C-O.; Gaskell, M.; Martin, E. A.; Heydon, R. T.; Farmer, P. B.; Bibby, M. C.; Cooper, P. A.; Double, J. A.; Bradshaw, T. D.; Stevens, M. F. G. Antitumor 2-(4-Aminophenyl) Benzothiazoles Generate DNA Adducts in Sensitive Tumor Cells in Vitro and in Vivo. Br. J. Cancer 2003, 88, 470-477.
49. Raunio, H.; Husgafvelpursiainen, K.; Anttila, S.; Hietanen, E.; Hirvonen, A.; Pelkonen, O. Diagnosis of Polymorphisms in Carcinogen-Activating and Inactivation Enzymes and Cancer Susceptibility - a review. Gene 1995, 159, 113-121.
50. Elias, A. D.; Wheeler, C.; Ayash, L. J.; Schwartz, G.; Ibrahim, J.; Mills, L.; McCauley, M.; Coleman, N.; Warren, D.; Schnipper, L.; Antman, K. H.; Teicher, B. A.; Frei, E. Dose Escalation of the Hypoxic Cell Sensitizer Etanidazole Combined With Ifosfamide, Carboplatin, Etoposide, and Autologous Hematopoietic Stem Cell Support. Clin. Cancer Res. 1998, 4, 1443-1449.
51. Patterson, L. H.; McKeown, S. R. AQ4N: A New Approach To Hypoxia-Activated Cancer Chemotherapy. Br. J. Cancer 2000, 83, 1589-1593.
52. Patterson, L. H. Bioreductively Activated Antitumor N-Oxides: the Case of AQ4N, A Unique Approach To Hypoxia-Activated Cancer Chemotherapy. Drug Metab. Rev. 2002, 34, 581-592.
53. McKeown, S. R.; Hejmadim M. V.; McIntyre I. A.; McAleer, J. J. A.; Patterson, L.H. AQ4N - An Alkylaminoanthraquinone N-Oxide Showing Bioreductive Potential and Positive Interaction With Radiation in Vivo. Br. J. Cancer 1995, 72, 76-81.
54. Patterson, L. H. Rationale For the Use of Aliphatic N-Oxides of Cytotoxic Anthraquinones As Pro-Drug DNA Binding Agents: A New Class of Bioreductive Agent. Cancer Met. Rev. 1993, 12, 119-134.
55. Raleigh, S. M.; Wanogho, E.; Burke, M. D.; McKeown, S. R.; Patterson, L. H. Involvement of Human Cytochromes P450 (CYP) in the Reductive Metabolism of AQ4N, A Hypoxia Activated Anthraquinone Di-N-Oxide Pro-Drug. Int. J. Radiat. Oncol. Biol. Phys. 1998, 42, 763-767.
56. Raleigh, S. M.; Wanogho, E.; Burke, M. D.; Patterson, L.H. Rat Cytochromes P450 (CYP) Specifically Contribute To the Reductive Bioactivation of AQ4N, An Alkylaminoanthraquinone-Di-N-Oxide Anticancer Pro-Drug. Xenobiotica. 1999, 29, 1115-1122.
57. Patterson, L. H.; McKeown, S. R.; Robson, T. Gallagher, R.; Raleigh S. M.; Orr, S. Antitumour Pro-Drug Development Using Cytochrome P450 (CYP) Mediated Activation. Anticancer Drug Des. 1999, 14, 473-486.
58. Murray, G. I.; McFadyen, M. C. E.; Mitchell, R. T.; Cheug, Y. L.; Kerr, A. C.; Melvin, W. T. Cytochrome P450 CYP3A in Human Renal Cell Cancer. Br. J. Cancer 1999, 79, 1836-1842.
59. McAleer, J. J.; McKeown, S. R.; MacManus, M. P.; Lappin, T. R.; Bridges, J. M. Hypobaric hypoxia: a method for testing bioreductive drugs in vivo. Int. J. Radiat. Oncol. Biol. Phys. 1992, 23, 551-555.
60. Friery, O. P.; Gallagher, R.; Murray, M. M.; Hughes, C. M.; Galligan, E. S.; McIntyre, I. A.; Patterson, L. H.; Hirst, D. G.; McKeown, S. R. Enhancement of the Antitumour Effect of Cyclophosphamide By the Reductive Drugs AQ4N and Tirapazamine. Br. J. Cancer 2000, 82, 1469-1473.
61. Gallagher, R.; Hughes, C. M.; Murray M. M.; Friery, O. P.; Patterson, L. H.; Hirst, D. G.; Mckeown, S. R. the Chemopotentiation of Cisplatin By Novel Bioreductive Drug AQ4N. Br. J. Cancer 2001, 84, 625-629.
62. Sutter, T. R.; Tang, Y. M.; Hayes, C. L.; Wo, Y. Y. P.; Jabs, E. W.; Li, X.; Yin, H.; Cody, C. W.; Greenlee, W. F. Complete cDNA Sequence of A Human Dioxin-Induced Messenger-RNA Identifies A New Gene Subfamily of Cytochrome-P450 That Maps To Chromosome-2. J. Biol. Chem. 1994, 269, 13092-13099.
63. Murray, G. I.; Taylor, M. C.; McFadyen, M. C. E.; McKay, J. A.; Greenlee, W. F.; Burke, M. D.; Melvin, W. T. Tumor-Specific Expression of Cytochrome P450 CYP1B1. Cancer Res. 1997, 57, 3026-3031.
64. Chaib, H.; Cockrell, E. K.; Rubin, M. A.; Macoska, J. A. Profiling and Verification of Gene Expression Patterns in Normal and Malignant Human Prostate Tissues By cDNA Microarray Analysis. Neoplasia. 2001, 3, 43-51.
65. Hellmann, G. M.; Fields, W. R.; Doolittle, D. J. Gene Expression Profiling of Cultured Human Bronchial Epithelial and Lung Carcinoma Cells. Toxicol. Sci. 2001, 61, 154-163.
66. Islam, T. C.; Lindvall, J.; Wennborg, A.; Branden, L. J.; Rabbani, H.; Smith, C. I. E. Expression Profiling in Transformed Human B Cells: Influence of Btk Mutations and Comparison To B Cell Lymphomas Using Filter and Oligonucleotide Arrays. Eur. J. Immunol. 2002, 32, 982-993.
67. Vondracek, M. T.; Weaver, D. A.; Sarang, Z.; Hedberg, J. J.; Willey, J. C.; Warngard, L.; Grafstrom, R. C. Transcript Profiling If Enzymes Involved in Detoxification of Xenobiotics and Reactive Oxygen in Human Normal and Simian Virus 40 T Antigen-Immortalized Oral Keratinocytes. Int. J. Cancer 2002, 99, 776-782.
68. Rochat, B.; Morsman, J. M.; Murray, G. I.; Figg, W. D.; McLeod, H. L. Human CYP1B1 and Anticancer Agent Metabolism: Mechanism For Tumor-Specific Drug Inactivation? J. Pharmacol. Exp. Ther. 2001, 296, 537-541.
69. McFadyen M. C. E.; McLeod H. L.; Jackson, F. C.; Melvin, W. T.; Doehmer, J.; Murray, G. I. Cytochrome P450 CYP1B1 Protein Expression: A Noval Mechanism of Anticancer Resistance. Biochem. Pharmacol. 2001, 62, 207-212.
70. Hedley, M. L.; Strominger, J. L.; Urban, R. G. Plasmid DNA Encoding Target Naturally Processed Peptides Generates Cytotoxic T Lymphocyte Responses in Immunized Animals. Hum. Gene. Ther. 1998, 9, 325-332.
71. Lunsford, L.; McKeever, U.; Eckstein, V.; Hedley, M. L. Tissue Distribution and Persistence in Mice of Plasmid DNA Encapsulated in A PLGA-Based Microsphere Delivery Vehicle. J. Drug Targ. 2000, 8, 39-50.
72. Waxman, D. J.; Chen, L.; Hecht, J. E. D.; Jounaidi, Y. Cytochrome P450-Based Cancer Gene Therapy: Recent Advances and Future Prospects. Drug. Metab. Rev. 1999, 31, 503-522.
73. Jounaidi, Y. Cytochrome P450-Based Gene Therapy For Cancer Treatment: From Concept To the Clinic. Cur. Drug Des. 2002, 3, 609-622.
74. Kan, O.; Kingsman, S.; Naylor, S. Cytochrome P450-Based Cancer Gene Therapy: Current Status. Expert Opin. Biol. Ther. 2002, 2, 857-868.
75. Chen, L.; Waxman, D. J. Intratumoral Activation and Enhanced Chemotherapeutic Effect of Oxazaphophoines Following Cytochrome-P450 Gene-Transfer-Development of A Combined Chemotherapy Cancer Gene-Therapy Strategy. Cancer Res. 1995, 55, 581-589.
76. Schwartz, P. S.; Chong-Sheng, C.; Waxman, D. J. Enhanced Bystander Cytotoxicity of P450 Gcne-Directed Enzyme Pro-Drug Therapy By Expression of the Antiapoptotic Factor P35. Cancer Res. 2002, 62, 6928-6937.
77. McCarthy, H. O.; Yakkundi, A.; McErlane, V.; Hughes, C. M.; Keilty, G.; Murray, M.; Patterson, L. H.; Hirst, D. G.; McKeown, S. R.; Robson, T. Bioreductivc GDEPT Using Cytochrome P450 3A4 in Combination With AQ4N. Cancer Gene Ther. 2003, 10, 40-48.
78. Murray, G. I.; Taylor, V. E.; McKay, J. A.; Weaver, R. J.; Ewen, S. W.; Melvin, W. T.; Burke, M. D. The Immunohistochemical Localization of Drug-Metabolizing Enzymes in Prostate Cancer. J. Pathol. 1995, 177, 147-152.
79. McFadyen, M. C.; Cruiekshank, M. E.; Miller, I. D.; McLeod, H. L.; Melvin. W. T.; Haites, N. E.; Parkin, D.; Murray, G. I. Cytochrome P450 CYP1B1 Over-Expression in Primary and Metastatic Ovarian Cancer. Br. J. Cancer 2001, 85, 242-246.
80. Ingelman-Sundberg M. Implications of Polymorphic Cytochrome P450-Dependent Drug Metabolism For Drug Development. Drug Metab. Dispos. 2001, 29, 570-573.
81. Ekins, S.; Wrighton, S. A. Application of in Silico Approaches To Predicting Drug-Drug Interactions. J. Pharmacol. Toxicol. Meth. 2001, 45, 65-69.
82. Murray, G. I.; Melvin, W. T.; Greenlee, W. F.; Burke, M. D. Regulation, Function, and Tissue-Specific Expression of Cytochrome P450 CYP1B1. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 297-316.
83. Stoilov, I.; Akarsu, A. N.; Sarfaraz, E. I. M. Identification of Three Different Truncating Mutations in Cytochrome P4501B1 (CYP1B1) As the Principal Cause of Primary Congenital Glaucoma (Buphthalmos) in Families Linked To the GLC3A Locus on Chromosome 2p21. Hum. Mol. Genet. 1997, 4, 641-647.